• General Aspects of Neuroscience Drug Discovery and Development
• 55 min
  1. Is there a role for academia in drug discovery

  • Dr. Adrian J. Ivinson
• 33 min
  2. Receptor-channel research at the interface between academia and pharma

  • Prof. Mihaly Hajos
• Seizure Disorders
• 35 min
  3. Discovery of Levetiracetam (Keppra(R)): The first SV2A ligand for the treatment of epilepsy

  • Dr. Henrik Klitgaard
• 47 min
  4. Anti-seizure drugs: discovery and development

  • Dr. Roger Porter
• Alzheimer's Disease
• 54 min
  5. Abeta toxicity 1

  • Prof. Colin L. Masters
• 28 min
  6. Abeta toxicity 2

  • Prof. Colin L. Masters
• 68 min
  7. Targeting Aß oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease

  • Prof. William L. Klein
• 19 min
  8. Pathogenic mechanisms and therapeutic approaches for the tauopathies

  • Prof. Karen Duff
• 31 min
  9. Update on fluid biomarkers for neurodegenerative diseases

  • Prof. Henrik Zetterberg
• Parkinson's Disease
• 51 min
  10. Disease-modifying therapies for Parkinson's disease

  • Dr. Todd Sherer
• Schizophrenia
• 20 min
  11. Discovery of schizophrenia drug targets from DISC1 mechanisms

  • Prof. Atsushi Kamiya
• 33 min
  12. Animal models for schizophrenia

  • Dr. Mikhail Pletnikov
• Archived Lectures *These may not cover the latest advances in the field
• 23 min
  13. Biomarkers for Alzheimer's disease

  • Prof. Henrik Zetterberg

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Schizophrenia
3. Modeling schizophrenia
4. Non-genetic models
5. Pharmacological models (1)
6. Pharmacological models (2)
7. Pharmacological models (3)
8. Symptoms similarity models (1)
9. Mouse sociability test
10. Symptoms similarity models (2)
11. Etiological non-genetic models (1)
12. Etiological non-genetic models (2)
13. Etiological non-genetic models (3)
14. Etiological non-genetic models (4)
15. Genetic models (1)
16. Genetic models (2)
17. Genetic models (3)
18. Genetic models (4)
19. Genetic models: Genome-wide association
20. Genetic models: Copy number variation (1)
21. Genetic models: Copy number variation (2)
22. Genetic models: Linkage studies
23. DISC1 gene
24. DISC1 animal models
25. Inducible mutant DISC1 model
26. Tet-off system (1)
27. No gross developmental defects
28. Hyperactivity
29. Elevated aggressiveness
30. Enlargement of the lateral ventricles (1)
31. The nature of DISC1 animal model
32. Why study timing?
33. Tet-off system (2)
34. Aggression in male mice
35. Enlargement of the lateral ventricles (2)
36. Caveats of genetic mouse models
37. New approaches (1)
38. New approaches (2)
39. Gene-environment interaction (GEI) models
40. Challenges of GEI models
41. Concluding remarks
42. Acknowledgements

Topics Covered

• Animal models for schizophrenia
• Animal models of psychiatric disorders
• Non-genetic animals models
• genetic animal models
• DISC1 anima models
• Weaknesses of the current animal models for schizophrenia
• Future directions in developing animal models for schziophrenia

Links

Series:

• Animal Models in Biomedical Research
• Drug Discovery and Development in the Neurosciences

Categories:

• Methods
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on March 28, 2013

Financial Disclosures

• Dr. Mikhail Pletnikov has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.